EP4377314A4 - BICYCLIC PGDH INHIBITORS AND METHODS OF MAKING AND USING THEM - Google Patents

BICYCLIC PGDH INHIBITORS AND METHODS OF MAKING AND USING THEM

Info

Publication number
EP4377314A4
EP4377314A4 EP22850242.3A EP22850242A EP4377314A4 EP 4377314 A4 EP4377314 A4 EP 4377314A4 EP 22850242 A EP22850242 A EP 22850242A EP 4377314 A4 EP4377314 A4 EP 4377314A4
Authority
EP
European Patent Office
Prior art keywords
bicyclic
making
methods
pgdh inhibitors
pgdh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22850242.3A
Other languages
German (de)
French (fr)
Other versions
EP4377314A1 (en
Inventor
Sundeep Dugar
Bruce Fahr
Roopa Rai
Michael J. Green
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epirium Bio Inc
Original Assignee
Epirium Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epirium Bio Inc filed Critical Epirium Bio Inc
Publication of EP4377314A1 publication Critical patent/EP4377314A1/en
Publication of EP4377314A4 publication Critical patent/EP4377314A4/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP22850242.3A 2021-07-28 2022-07-27 BICYCLIC PGDH INHIBITORS AND METHODS OF MAKING AND USING THEM Pending EP4377314A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163226671P 2021-07-28 2021-07-28
US202163226673P 2021-07-28 2021-07-28
PCT/US2022/038515 WO2023009618A1 (en) 2021-07-28 2022-07-27 Bicyclic pgdh inhibitors and methods of making and using

Publications (2)

Publication Number Publication Date
EP4377314A1 EP4377314A1 (en) 2024-06-05
EP4377314A4 true EP4377314A4 (en) 2025-06-18

Family

ID=85087971

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22850242.3A Pending EP4377314A4 (en) 2021-07-28 2022-07-27 BICYCLIC PGDH INHIBITORS AND METHODS OF MAKING AND USING THEM

Country Status (2)

Country Link
EP (1) EP4377314A4 (en)
WO (1) WO2023009618A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115335043B (en) 2020-01-23 2025-03-28 迈欧伏特治疗公司 PGDH inhibitors and methods of preparation and use
EP4655301A1 (en) * 2023-01-25 2025-12-03 Epirium Bio Inc. Pgdh inhibitors and methods of making and using
WO2025155638A1 (en) * 2024-01-16 2025-07-24 Epirium Bio Inc. Compositions and methods for treating obesity and diabetes using 15-pgdh inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990146A (en) * 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
WO2013123215A2 (en) * 2012-02-17 2013-08-22 Siga Technologies, Inc. Antiviral drugs for treatment of arenavirus infection
WO2021151014A1 (en) * 2020-01-23 2021-07-29 Myoforte Therapeutics, Inc. Pgdh inhibitors and methods of making and using

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010239188B2 (en) * 2009-04-22 2016-03-31 Janssen Pharmaceutica Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
US12304897B2 (en) * 2019-01-31 2025-05-20 Kyorin Pharmaceutical Co., Ltd. 15-PGDH inhibitors
EP3982957A4 (en) * 2019-06-11 2023-06-21 The Board of Trustees of the Leland Stanford Junior University METHOD OF REJUVENATING AGED TISSUE BY INHIBITION OF 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE (15-PGDH)
AU2021361071A1 (en) * 2020-10-15 2023-06-15 Epirium Bio Inc. Inhaled formulations of pgdh inhibitors and methods of use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990146A (en) * 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
WO2013123215A2 (en) * 2012-02-17 2013-08-22 Siga Technologies, Inc. Antiviral drugs for treatment of arenavirus infection
WO2021151014A1 (en) * 2020-01-23 2021-07-29 Myoforte Therapeutics, Inc. Pgdh inhibitors and methods of making and using

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DUVEAU DAMIEN Y. ET AL: "Structure-activity relationship studies and biological characterization of human NAD+-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 24, no. 2, 1 January 2014 (2014-01-01), Amsterdam NL, pages 630 - 635, XP093256163, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2013.11.081 *
OUVRY GILLES ET AL: "Discovery of phenoxyindazoles and phenylthioindazoles as ROR[gamma] inverse agonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, ELSEVIER, AMSTERDAM NL, vol. 26, no. 23, 12 October 2016 (2016-10-12), pages 5802 - 5808, XP029815424, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2016.10.023 *
See also references of WO2023009618A1 *

Also Published As

Publication number Publication date
WO2023009618A1 (en) 2023-02-02
EP4377314A1 (en) 2024-06-05

Similar Documents

Publication Publication Date Title
EP3968999A4 (en) FGFR INHIBITORS AND METHODS OF USE THEREOF
MA54261A (en) PCSK9 INHIBITORS AND METHODS OF USE THEREOF
EP3911640A4 (en) PCSK9 INHIBITORS AND METHODS OF USE THEREOF
EP4236990A4 (en) INTERLEUKIN-18 VARIANTS AND METHODS OF USE THEREOF
MA55885A (en) MACROCYCLIC CHELATORS AND METHODS OF USE THEREOF
EP3962479A4 (en) KCNT1 INHIBITORS AND METHODS OF USE
EP3962481A4 (en) KCNT1 INHIBITORS AND METHODS OF USE
EP3920772A4 (en) MULTI-LAYER SPECULUM AND METHODS OF MAKING AND USING IT
EP4125831A4 (en) KCNT1 INHIBITORS AND METHODS OF USE
EP3917508A4 (en) MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF
EP4291193A4 (en) EGFR DEGRADING AGENTS AND METHODS OF USE
EP3924159A4 (en) VACUUM ANCHORS AND METHOD OF MANUFACTURING THEREOF
EP3959334A4 (en) HYBRIDIZATION COMPOSITIONS AND METHODS OF MAKING AND USING THEIR
EP4255399A4 (en) SEMI-SOLID PED5 INHIBITOR COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
MA51837A (en) ARGINASE INHIBITORS AND METHODS OF USE THEREOF
EP4329521A4 (en) COLLAGEN COMPOSITIONS AND METHODS OF USE THEREOF
EP4175624A4 (en) KCNT1 INHIBITORS AND METHODS OF USE
EP4267133A4 (en) KCNT1 INHIBITORS AND METHODS OF USE
EP3740193A4 (en) SEMI-SOLID ANTI-HISTAMINE COMPOSITIONS AND METHODS OF MAKING AND USING SAME
EP3966248A4 (en) HUMANIZED ANTIBODIES TO MUCIN-16 AND METHODS OF USE THEREOF
EP3630772A4 (en) METHODS OF MANUFACTURING AND USE OF PDE9 INHIBITORS
EP4164653A4 (en) MORPHIC FORMS OF TRILACICLIB AND METHODS OF MANUFACTURING THEM
EP4223500A4 (en) LAMINATE AND METHOD OF USING LAMINATE
EP3930862A4 (en) COMPOSITION AND METHOD OF MAKING GRIPS
MA56545A (en) ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240222

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20250519

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 9/08 20060101ALI20250513BHEP

Ipc: A61K 31/454 20060101ALI20250513BHEP

Ipc: C07D 401/06 20060101ALI20250513BHEP

Ipc: C07D 401/14 20060101ALI20250513BHEP

Ipc: C07D 471/04 20060101AFI20250513BHEP